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Heparan sulfate (HS) is a highly acidic linear polysaccharide with a very variable structure.
It is ubiquitously expressed on cell surfaces and in the extracellular matrix and basement
membrane of mammalian tissues. Synthesized attached to various core proteins to form
HS-proteoglycans, HS is capable of interacting with various polypeptides and exerting
diverse functions. In fact, a bioinformatics analysis of mammalian proteins that express
a heparin/HS-binding motif and are associated with the immune system identified 235
candidate proteins, the majority having an intracellular location. This simple analysis sug-
gests that HS may, in fact, interact with many more components of the immune system
than previously realized. Numerous studies have also directly demonstrated that HS plays
multiple prominent functional roles in the immune system that are briefly reviewed in this
article. In particular, the molecule has been shown to regulate leukocyte development,
leukocyte migration, immune activation, and inflammatory processes.
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INTRODUCTION
Heparan sulfate (HS) is a glycosaminoglycan (GAG) that is ubiq-
uitously expressed on cell surfaces and in the extracellular matrix
(ECM) and basement membrane (BM). Each HS molecule is
a linear polysaccharide composed of repeating disaccharides of
hexuronic acid and d-glucosamine that can exhibit immense
structural diversity due to substitution to varying extents with
sulfate groups and epimerization of glucuronic acid to iduronic
acid, with areas of high sulfation and glucuronic acid epimer-
ization being co-located in “hot spots” throughout the molecule
(Figure 1). HS is structurally related to heparin, an extremely
highly sulfated form of HS that is restricted to mast cells. The
biosynthesis and modification of HS chains is thought to take
place within the endoplasmic reticulum, Golgi apparatus, and
trans Golgi network, which in the end produce unique HS chains
that are covalently attached to a range of core proteins to form
HS-proteoglycans (HSPG) (Figure 1) (1, 2). After synthesis HS
chains can be modified by the endoglycosidase, heparanase (3),
and endosulfatases, Sulf1 and Sulf2 (4–6), to regulate HS avail-
ability and function. Although the core proteins can function
independently of the HS chains they carry (7), HS predominantly
dictates the ligand-binding capability and therefore the biological
roles of HSPG (8). Furthermore, while different cell types may
express similar core proteins, the HS chains these core proteins
carry can be markedly distinctive, resulting in HSPG with highly
diverse yet specialized roles in mammalian physiology (8, 9). In this
mini-review, we will discuss some of the contributions of HS to
the functioning of the immune system, notably leukocyte develop-
ment, leukocyte migration, immune activation, and inflammatory
processes.
DIFFERENT CELLULAR LOCATIONS OF HS CHAINS
In general, cell surface HSPGs includes members of the trans-
membrane syndecans (syndecan-1-4) and glycosylphosphatidyli-
nositol (GPI)-linked glypicans (glypican 1-6). ECM/BM associ-
ated HSPGs are comprised of perlecan, collagen type XVIII and
agrin. These HSPGs are collectively termed “full-time” HSPGs.
“Part-time” HSPG include cell surface CD44 (isoform 3 is HS-
linked) and extracellular betaglycan, testican, and neuropilin (8,
10). Secretory vesicle-associated serglycin is a HSPG that is exclu-
sively expressed intracellularly, particularly in mast cells (11).
Furthermore, HSPG can also be localized in the nucleus where
they potentially regulate gene transcription (12–16).
PREVALENCE OF HS-BINDING PROTEINS IN THE
MAMMALIAN IMMUNE SYSTEM
Due to the structural similarities between HS and heparin, the lat-
ter is often used as an experimental model for biochemical studies
of HS-protein interactions and predicting potential HS-binding
partners. Several heparin-binding proteins are known to carry
the “consensus” heparin/HS-binding motifs XBBXBX or XBB-
BXXBX (B being the basic amino acids arginine, lysine, or histidine
and X being one of a range of aliphatic/aromatic amino acids)
(17). If correctly displayed in the secondary structure and opti-
mally positioned within the three-dimensional conformation of
polypeptides, these sequences are hypothetically capable of facil-
itating strong ionic interactions with negatively charged GAGs
(17, 18). Based on this simple amino acid sequence criterion, we
screened for protein sequences matching selected G0 terms in the
Ensembl database (release 72) with a custom Python script for
murine gene products that carry these motifs and are listed on the
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UniProt database (www.uniprot.org) as being reported to have
immunological functions. We identified a total of 235 HS-binding
proteins in the mouse genome (Table 1), a list that includes known
FIGURE 1 |The structure of HSPG. HS chains (blue line) are linear
polysaccharides composed of repeating disaccharide subunits, which in
their unmodified form are D-glucosamine and D-glucuronic acid (blue box).
During synthesis, HS chains are covalently attached to core proteins (open
circles) at serine (S) residues. A single HSPG molecule may carry multiple
HS chains or contain other glycosaminoglycans other than HS (not shown).
HS modifications include various degrees of O and N-sulfation and
epimerization of D-glucuronic acid to D-iduronic acid by HS-modifying
enzymes (red box) (1). The modifications occur in regions (hot spots) along
the polysaccharide chain, these hot spots being separated by regions of low
sulfation. Post-synthesis structural alterations are primarily mediated by the
endo-β-glucuronidase, heparanase, which cleaves HS chains within highly
sulfated regions (cleavage site indicated by red scissors and arrow) (3).
HS-binding proteins and many potential new ligands for HS. An
intriguing feature of this analysis was that 66% of the molecules
that potentially bind HS are expressed intracellularly, with only
18% being exclusively expressed on the cell surface and only 10%
being in the extracellular compartment. Remarkably, only one
HS-binding protein, the HS degrading enzyme heparanase, was
identified that can be expressed in intracellular and extracellular
compartments as well as being able to associate with plasma mem-
branes. This finding is consistent with the multiple functional roles
of the enzyme.
Despite earlier reports claiming that HS negatively regulates
gene transcription primarily by repressing the activity of p300
and pCAF histone acetyltransferase (14, 15), the bioinformat-
ics screen implies that intracellular HS plays a more elaborate
role in dictating cellular responses to various stimuli. Thus, it is
predicted that HS interacts with several regulators of histone-
modifying enzymes, such as Jarid2 (motif: MKRRHI), Kat6a
(LHHLRM, KKVKK, RRVRK), and Mll1 (LRRFRA, IKKLRA,
LKKAKA, VHRIRV, KKVKR, RHLKK) alongside key molecules
that are involved in signal transduction and regulation of gene
transcription, notably Vav1 (VKHIKI), STAT5A (KRIKR), STAT6
(KKIKR), Bcl6 (WKKYKF), Bcl11a (KHMKK), Ciita (LKRLKL),
PTBP3 (VHRVKI, HRFKK), Lck (VKHYKI), IRAK1 (RRAKK),
IRAK4 (HHIHR), Foxj1 (FKKRRL), Syk (RKAHH), ITK/TSK
(IKHYHI), Card11 (KRFRK), Zap70 (KKLFLKR), Jak3 (IHKLKA,
AKKLKF, RRIRR), and Cblb (RHFHH) and some components
of the NF-κβ signaling pathway including NFKB2 (YHKMKI),
Table 1 | Hypothetical HS-interacting proteins.
Cellular location Total Protein
Intracellular 154 Nlrp3, Nkap, Lrp5, Lyst, Lck, Irak4, Sla2, Mx2, Syk, Oasl2, Tcf3, Myo1e, Atp7a, Cplx2, Tusc2,
Ak7, Vav3, Blnk, Spta1, Skap1, Fgr, Pmaip1, Aim2, Shb, Ddx60, Dapk3, Nfkb2, Apobec3,
Ripk2, Nod1, Sptb, Oas1d, Mapk14, Ptbp3, March8, Dapk1, Zfp385a, Bcl2, Mecom, Chd7,
Gpam, Ap3d1, Lcp2, Arid4a, Polr3a, Tnfaip1, Kat6a, Ung, Myo9b, Bcl6, Eprs, Sp3, Bag6,
Plcg1, Nbn, Pml, Klf1, Rb1, Sfxn1, Bcl11a, Farp2, Jarid2, Xrcc6, Itk, Myo1f, Nlrc5, Cyp27b1,
Ikzf1, Ddx58, Pip4k2a, Ciita, Foxj1, Rnf168, Prkdc, Pms2, Mll1, Stk3, Mef2c, Ahctf1, Prkx,
Rag1, Batf3, Map3k14, Ilf2, Herc6, Card11, Card9, Dlg1, Itch, Dyrk3, Tnip3, Cdk6, Irgm1,
Rnf31, Apc, Unc13d, Tlr13, Tlr8, Nedd4, Msh6, Pcid2, Sh2b2, Aicda, Myh9, Pik3cd, Zap70,
Vav1, Stat5a, Tgtp1, Mx1, Enpp2, Dock2, Pgm3, Unc93b1, Plcg2, Stxbp2, Ifi44l, Zfp35,
Inpp5d, Oas3, Cblb, Ostm1, Bcl11b, Eps8, Prkd1, Ctnnbl1, Polr3b, Samhd1, Nlrc4, Tec, Tet2,
Map3k5, Pou1f1, Ncaph2, Stat6, Smarca4, Fnip1, Jak3, Cactin, Dicer1, Atm, Ikbkg, Satb1,
Eif2ak2, Stap1, Msh3, Sgpl1, Cdk13, Foxe1, Zc3h8, Spib, Maea, March1, Ank1, Mink1
Plasma membrane 42 Mpzl2, Adam10, Ntrk1, Icosl, Cxcr5, Cd97, Tlr6, Pde2a, Adam9, Tlr1, Ccr3, Treml2, Tril, Tek,
Lrrc8a, Il2ra, Selp, Fas, Hfe, Cd83, Cd22, Ccbp2, Ctla4, Tlr2, Klre1, Gpr183, Ccr7, Abcc9,
Hoxb4, H2-M5,Thsd1, Dcstamp, Il7r, Procr, Amica1, Chrnb2,Tnfrsf13c, Csf1r, Tlr4, Tyr, Cd93,
Eda, Cd40lg
Extracellular 24 Masp1, Ccl25, Osm, Il9, Bmp4, Inhba, Pdgfb, Scg2, Hc, Fam20c, Wnt2b, Lrrc17, Gas6, C7,
Il1a, Wnt5a, Cxcl12, AI182371, C4b, Cxcl5, C8b, Ccl17, Serping1, Ccl28
Intracellular, plasma membrane, and extracellular 1 Hpse
Intracellular and plasma membrane 3 Blk, Flt1, Flt3
Intracellular and extracellular 2 Isg15, Prg4
Plasma membrane and extracellular 8 Tgfb1, Vegfa, Enpp3, Ctsg, C8a, Ptpro, Adam17, Enpp1
List of murine proteins that carry “consensus” heparin/HS-binding motifs. The motifs adapted for bioinformatic screens are the standard motifs, which are primarily
XBBBXXBX or XBBXBX (17) (http:// gduserv.anu.edu.au/ ~cameron/ protein.html). Short motifs are truncated versions of the standard motifs XBBBBX, BBXBB, or
BBXXXBB (B=basic amino acids R, K, H; X=A, V, I, L, M, F, Y, W). Only proteins in the UniProt database (www.uniprot.org) that are known to play immunological
roles are listed.
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IKBKG (MRKRHV), and Nkap (RRAKK, KKAKK, KKYKK).
Interestingly, in the Rag1 protein, the presence of a HS-binding
motif adjacent to a site critical for DNA binding (560D, UniProt)
(AKRFRY), and overlapping the site that is essential for DNA
hairpin formation [971F and 972R, UniProt (19)] (RRFRK), may
imply a role for HS in regulating V(D)J recombination.
It is not surprising that cytokines including IL-1α (LKKRRL),
IL9 (HRVKR), TGF-β1 (VKRKRI), and chemokines such as
CCL17 (KHVKK), CCL19 (RRLKK), CCL25 (ARKRLVHM),
CCL28 (VKRRRI), CXCL5 (KKAKR), and CXCL12 (VKHLKI)
also carry HS-binding motifs, presumably allowing HS to act as
their atypical receptors. Moreover, HS-binding motifs are also
present on the cognate receptors for soluble factors such as the
cytokine receptors IL-2Rα (HRWRK) and IL7R (KKVKH) and
the chemokine receptors CCR3 (WKFFHA), CCR7 (AHRHRA),
and CXCR5 (YRRRRL), indicating new roles for HS in regulating
leukocyte homeostasis and trafficking. In addition, HS may regu-
late the availability of crucial components in the immunological
synapse as indicated by the presence of HS-binding motifs in the
leader sequences of ICOSL (WKKLHV) and CTLA4 (LRRYKA).
The presence of HS-binding motifs in CD22 (KKARR) and
CD40L (KKLKR) also suggests additional roles for HS in cell-cell
communication and T cell costimulation.
Examination of the innate immune system reveals that,
although HS is already known to interact with TLR-4 (20), it
appears that HS may also be recognized by other TLRs, includ-
ing cell surface TLR-1, TLR-2, and TLR-6, and endosomal TLR-8
and TLR13. To be more precise, the HS-binding motifs appear
to be in the extracellular domains of TLR-4 (RHIFWRR) and
TLR-2 (IRRLHA) and in the cytoplasmic domains of TLR-1
(HRARH) and TLR-6 (YHKLRA and HRARH). For the endo-
somal TLRs, both motifs (LKKLHL and LKKKHF) are facing
luminal for TLR-8, and cytoplasmic (HRLRK) and luminal (LKR-
LKI) for TLR13. It is possible that HS is involved in regulating
downstream signaling when the motifs are present in the TLR
cytoplasmic domains. In contrast, when these motifs are fac-
ing the luminal or extracellular space, HS may be a ligand or a
regulatory component that modulates the interaction between a
TLR and its cognate ligands. Furthermore, HS-binding motifs
are also present on inflammasome components such as Nlrp3
(LKKFKM), Nlrc4 (LKKMRL, RHIHR), and Aim2 (LKRFKY),
implicating a role for HS in regulating the activation of inflam-
matory caspases. In another aspect of innate immunity, several
studies have reported that heparin and HS are able to interact
with several components of the complements system, includ-
ing C1 (21), C1q, C1 inhibitor, C2, C4, C4b, C4bp, C6, C8,
C9, Factor B, Factor D, Factor H (22), MASP1, MASP-2 (23),
and complement receptors CR3 (CD11b/CD18) (24) and CR4
(CD11c/CD18) (25). In support of these observations, we have
identified the presence of HS-binding motifs in complement pro-
teins such as C4b (FRKFHL), Hc/complement C5 (FHKYKV),
C7 (KRLYLKR), C8a (WRKLRY), and C8b (KRYRH) as well as
regulatory components of the complement machinery including
MASP-1 (KHWRR), Serping1 (HKIRK), and CD93/complement
component C1q receptor (YHKRRA), further highlighting the
role of HS as a major modulator of the complement sys-
tem (26).
However, it should be noted that more in-depth analyses are
required to assess the validity of these predicted interactions, in
particular the demonstration that the predicted HS-binding sites
are correctly presented within the secondary structure and final
three-dimensional conformation of the putative HS-binding pro-
teins. Also, there are known HS-binding proteins that lack the
heparin/HS-binding motifs used in this analysis, suggesting that
the list of binding proteins identified in this screen may, in fact,
be an under estimate. Thus, at face value, the data set implies that
a wide range of HS-binding proteins participate in the immune
system.
FUNCTIONAL ROLES OF HS IN IMMUNITY
Despite the previous section suggesting that there are many
unknown HS-protein interactions that may control the immune
system, there are a number of well-established functional roles
for HS in immunity. Indeed HSPGs, through their HS chains, are
involved in a broad spectrum of biological processes, profoundly
influencing development (27), homeostasis (28), and the progres-
sion of many diseases (29). In the case of the immune system,
HSPGs are fundamentally involved in regulating cell adhesion,
cytokine and chemokine function, sensing tissue injury, and medi-
ating inflammatory reactions. Each of these functional roles will
be briefly discussed below, with specific examples given which
highlight each function.
REGULATOR OF CELL ADHESION
Cell adhesion molecules are important to facilitate and regulate
cell-cell signaling, migration and activation of leukocytes during
development, homing, and recruitment to inflammatory sites. For
example, of particular relevance to leukocytes development in the
bone marrow is the receptor complex on hematopoietic stem cells
(HSCs) comprised of CD45 and Mac-1 (CD11b/CD18) that has
been shown to bind to surface HS on bone marrow-derived stro-
mal cells and facilitate strong adhesion (30). In a related study, the
HSPG glypican-3 enhances the antagonizing effect of tissue factor
pathway-inhibitor (TFPI) on CD26, the stromal-bound ectopep-
tidase that is involved in cleaving surface CXCL12, a typical ligand
for CXCR4 on HSC. As a result, glypican-3 indirectly supports the
directional homing of grafted HSC toward, and their retention in,
the bone marrow (31). Similarly, in the thymus a particular subset
of cortical epithelial cells known as thymic nurse cells are reported
to express high levels of highly sulfated HS that is thought to aid
thymocyte adhesion and facilitate T cell development (32–35).
During an inflammatory response, HS positively regulates the
recruitment of inflammatory cells at three different stages based
on the following observations. First, endothelial surface HS can
reduce neutrophil rolling velocity via L-selectin-mediated cell
adhesion (36). Second, once attached, the HS-mediated Mac-1-
CD44v3 interaction enhances the binding of leukocytes to the
endothelial surface to drive extravasation (37). Finally, within
the endothelial ECM/BM, collagen type XVIII promotes leuko-
cytes infiltration in again an L-selectin-dependent manner (38,
39). However, the role of HS in the adhesion of leukocytes to
the endothelium can occur paradoxically, in a biphasic manner.
Under physiological conditions, glycocalyx HSPGs of pulmonary
endothelial cells are known to impede neutrophil adhesion (40).
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Following the induction of an experimental sepsis model of acute
lung injury, the localized production of TNF-α activates endothe-
lial cells to produce heparanase, which in turn catalyzes the par-
tial degradation of HS constituents of the glycocalyx. The loss
of HS results in a significant increase in neutrophils binding
(40), presumably via neutrophils L-selectin binding to residual
endothelial HS and via cytokine-induced endothelial P- and E-
selectin (41). Additionally, reduction (in wild-type mice) or dele-
tion (in knockout mice) of syndecan-1 from murine endothelial
cells strongly accentuates antigen-specific lymphocytes infiltra-
tion into inflammatory sites during a delayed-type hypersensitivity
reaction (42).
MODULATOR OF CYTOKINE AND CHEMOKINE FUNCTION
Soluble factors, such as cytokines and chemokines, are crucial to
support growth, maintain homeostasis, and orchestrate immune
cell trafficking across various locations. However, some of these
molecules are inactive or susceptible to degradation in their native,
soluble form. Furthermore, these factors need to be timely pre-
sented at the right site to exert their anticipated functions. HSPGs
have been implicated in modulating various aspects of cytokine
and chemokine function (43, 44).
HS-proteoglycans interact with various cytokines primarily on
target cells or act as atypical cytokine receptors on cytokine pre-
senting cell. The former situation enables HPSGs to regulate the
availability and influence the interaction between cytokines and
their cognate receptors on target cells. For example, the binding of
cell surface HS to cytokines such as IL-7 and IFN-γ proved criti-
cal to protect them against proteolysis (45, 46). Furthermore, the
lack of HSPG expression on the mouse pro-B cell surface severely
impairs IL-7-dependent maturation toward pre-B cells suggesting
that in this situation HS acts as a primary IL-7 receptor. In addi-
tion, HSPG can contribute to IL-7 biological activity by presenting
IL-7 on stromal cells to promote lymphopoiesis in the bone mar-
row (47). In the thymus, however, the ability of stromal cell HSPGs
to bind IL-7 and aid thymocytes development is dispensable (48).
Depending on the degree of sulfation, cell surface HSPG has also
been shown to potentiate the IFN-γ-IFN-γ-receptor interaction
(49). Importantly, HSPG also facilitate cytokine localization in
specific niches, forming depots where they can be made available
to target cells. For instance, perlecan binds IL-2, sequestering it
from the circulation and subsequently depositing the cytokine in
the marginal zone and red pulp of the murine spleen to mod-
ulate murine T cells homeostasis (50). HSPGs also facilitate the
storing of IL-2 within the vascular smooth muscle wall where
cytokine availability is regulated through heparanase-mediated
ECM degradation (51).
The ability to bind and present a chemokine to target cells is
insufficient to drive cell migration, the hallmark of chemokine
function. HSPGs are not only capable of binding and assisting in
inducing conformational changes in bound chemokines (52, 53),
but also contribute to the establishment of immobilized (haptotac-
tic) chemokine gradients in tissues (54). For example, HSPG facili-
tate the oligomerization of bound RANTES/CCL5, CXCL8, MCP-
1, and MIP-1, thereby allowing better recognition by their cognate
G-protein-linked transmembrane receptors (55). In addition to
the sequestration of CXCL2 (56), HSPG also mediate transcytosis
of CXCL8 across the endothelium, presenting both chemokines
on the luminal side and establishing haptotactic gradients that
aid neutrophils recruitment during inflammation (36). In a sepa-
rate study, the migration of tissue dendritic cells (DC) to regional
lymph nodes and the local positioning of DC within lymph nodes
was also found to be mediated by a HS-dependent haptotactic
gradient of CCL21 (57). A similar interaction is believed to facil-
itate lymphocytes homing through the high endothelial venules
into peripheral lymphoid organs (58, 59), although it is unclear
if HS also influences local positioning in specific niches. Also,
shedding of HSPG, such as syndecan-1 (60) and removal of glu-
cosamine 6-O-sulfate by the endosulfatase, Sulf2 (6) has been
implicated in regulating the interaction between HS and vari-
ous chemokines. Furthermore, the inactivation of HS-modifying
enzymes can modify neutrophil binding to the endothelium,
Ndst1 (HS N -deacetylase/N -sulfotransferase) deletion severely
impairing (36), while Hs2st (HS 2-O-sulfotransferase) deletion
significantly augmenting (61), neutrophil binding. These studies
support the concept of regulating HS function by altering the
availability of enzymes that are involved in HS biosynthesis.
A SENSOR OF TISSUE INJURY
Tissue injury may induce cell necrosis, an event that is often asso-
ciated with the release of various endogenous damage-associated
molecular pattern (DAMP)-containing molecules that are potent
inducers of inflammatory responses and initiators of tissue repair
mechanisms (62). Both surface bound HSPG and soluble HS par-
ticipate in sensing tissue injury and also in repair mechanisms. For
example, endothelial cell surface HS mediates the oligomerization
of the receptor for advanced glycation endproducts (RAGE) (63)
and together form a receptor complex that efficiently recognizes
the chromatin protein, high-mobility group protein B1 (HMGB1)
released from necrotic cells (64). As part of the tissue repair mech-
anism, HS on the surface of professional phagocytes also assists in
the clearance of necrotic cells (65). In fact, soluble HS itself can also
function as a DAMP (66) by interacting with TLR-4 on leukocytes
(20). This interaction has been shown to modulate the release of
pro-inflammatory cytokines by macrophages (67) and markedly
induce the maturation of DC, as indicated by the up-regulation
of MHC-II, CD40, ICAM-1, CD80, CD86, and reduced antigen
uptake, a typical phenotype of a professional antigen presenting
cells (68). Although this is beneficial in triggering immune activa-
tion following an insult (20), it is also implicated in the underlying
mechanism of disease progression which can occur in experi-
mental pancreatitis (69), sepsis-like syndrome (70), hyperacute
rejection in graft-versus-host disease (GvHD) (71), and cardiac
injury (72).
PHYSICAL BARRIER TO LEUKOCYTE MIGRATION
The ECM/BM associated HS is crucial to form a temporary depot
of HS-binding soluble factors and to form a physical barrier that
supports tissue integrity. In order to migrate, particularly through
blood vessel walls, leukocytes need to break down the ECM/BM
barrier and heparanase is primarily involved in this process (10,
73). For example, tissue DCs increase the availability of cell surface
heparanase to aid ECM degradation before migrating into lym-
phatic vessels leading toward regional lymph nodes where they
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induce antigen-specific responses (74). Subsequent studies have
suggested that the matrix metalloproteinase, MMP-14, coopera-
tively works with heparanase to more efficiently degrade ECM/BM
barriers (75). During inflammation, infiltrating monocytes and
neutrophils also exhibit similar modes of degrading ECM/BM
barriers to aid their extravasation (76, 77). It has also been demon-
strated that heparanase derived from infiltrating leukocytes is
primarily responsible for the destruction of the pancreatic islet β-
cells that produce insulin, thereby providing a novel explanation
for the underlying immunopathology of autoimmune Type 1 dia-
betes (78). In a separate study, leukocytes were shown to also use
endogenous myeloperoxidase to produce oxidants that degrade
the core protein of perlecan, releasing soluble factors and allowing
leukocyte migration across ECM/BM barriers (79). Although HS
can also be degraded by nitric oxide (80, 81) and reactive oxy-
gen species (82–84), their direct relevance in the degradation of
ECM/BM-associated HSPGs and therefore their contribution to
leukocytes extravasation is yet to be elucidated.
CONCLUDING REMARKS
The evidence presented in this mini-review further corroborates
the fundamental importance of HS in the mammalian immune
system. HSPGs, primarily through their HS side chains, regulate
various aspects of the immune system ranging from hematopoiesis
to homing of leukocytes to peripheral tissues and, most impor-
tantly, regulating the elicitation of immune responses. Perturbing
HS function or availability has been proven to results in various
abnormal immune phenotypes. Furthermore, based on a sim-
ple bioinformatics screen presented in this review, it is suggested
that HS may in fact interact with many more components of the
immune system than previously realized. A better understanding
of HS function across various systems is fundamental to exploit
its potential in boosting beneficial immune responses and also in
finding treatments for related immunopathologies.
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